Proceedings of the Nutrition Society (2021), 80 (OCE2), E65

CrossMark

Spring Conference, 29-30 March 2021, Gut microbiome and health

The effect of lactobacillus gaseeri THT 031301 supplementation on the body composition and inflammation in adults: pilot study

H. Hamdallah¹, D. Lucas², B. Kestecher³ and N. Abdel Azim¹

¹Chester Medical School, University of Chester, Chester, UK, ²Faculty of Health, Liverpool John Moores University, Liverpool, UK and

³Faculty of Medicine, Semmelweis University, Budapest, Hungary

Human guts are occupied with 100-1000 microbial species which plays a significant role in the host health and disease⁽¹⁾. Lactobacillus species have shown a paradoxical effect in relation to body composition. Clinical trials using lactobacillus gasseri (L. gasseri) have demonstrated an anti-obesity effect, exhibiting significant reductions in visceral and subcutaneous fat, body weight, body mass index (BMI), and waist and hip circumferences⁽²⁾. Moreover, L. gasseri has contributed to the regulation of abdominal obesity and showed a potential immunomodulatory effect in infants as well as boosting the immune system of healthy adults^(3, 4). Rodent models have found an association between the presence of L. gasseri and positive outcomes in relation to weight loss, fasting blood glucose (FBS)⁽⁵⁾, and inflammation⁽⁶⁾. The aim of this study to look at the effect of 4 weeks of supplementation with L. gasseri THT 031301 on obesity, glycaemic, and inflammatory markers.

This is a single centre, double-blind, randomised, placebo-controlled pilot study that recruited fourteen adult subjects with BMI > 25 kg/m2, who were randomly assigned to receive either a supplement containing L. gasseri THT 031301 (n = 6) or a placebo (n = 7). Pregnant and lactating women, subjects on anti-diabetic medications, and subjects who have undergone heart surgery have been excluded. Consented subjects were asked to consume 2 capsules per day continuously for 4 weeks. L. gasseri THT 031301 daily dosage was approximately 6x 109cfu. Alterations in obesity markers were assessed using BMI and waist-to-height ratio (WtHR), and inflammatory markers were measured using enzyme-linked immunosorbent assay (ELISA). FBS level, HBA1c, and insulin measured to indicate the glycaemic markers. Each marker measured at baseline and after 4 weeks.

After 4-weeks supplementation, a significant reduction in waist circumference (WC) (P = 0.022) and (WtHR) (P = 0.035) was identified in the THT 031301 compared to the placebo. Within-group comparisons attributed this finding to a significant increase in WC $(93.4 \pm 10.1 \text{ vs } 94.6 \pm 9.5, P = 0.040)$ and WtHR $(0.55 \pm 0.04 \text{ vs } 0.56 \pm 0.04, P = 0.047)$ in the placebo group. THT 031301 identified a small increase in the anti-inflammatory cytokine IL-10; however, this was not statistically significant. No changes were identified with the glycaemic markers HbA1c, fasting blood glucose, or insulin.

The current pilot study suggests a potential anti abdominal obesity effect of L. gasseri THT 031301 on the glycaemic markers in healthy adults, but this effect needs to be investigated in a large adequately powered RCT. The study did not find a significant effect of L. gasseri THT 031301 on the glycaemic markers. Future studies might recruit obese and overweight subjects or subjects with diabetes to confirm the anti-obesity, anti-diabetic and anti-inflammatory effect of L. gasseri THT 031301.

Acknowledgements

We would like to thank all the participants for taking part in this trial.

References

NS Proceedings of the Nutrition Society

- Kerry RG, Patra JK, Gouda S, *et al.* (2018) *J Food Drug Anal*, **26**(3), 927–939. Olivares M, Díaz-Ropero MP, Gómez N *et al.* (2006) *Int Microbiol* **9**(1), 47–52. Oh NS, Joung JY, Lee JY & Kim Y. (2018) *PlotS one* **13**(2), e0192021.
- 3.
- Kadooka, Y., Sato, M., Imaizumi, K *et al.* (2010) *Eur J Clin. Nutr* **64**(6), 636–643. Million M, Angelakis E, Paul M, *et al.* (2012) *Microb Pathog.* **53**(2),100–8.
- Yun SI, Park HO, Kang JH (2009) J Appl Microbiol 107(5), 1681-6.